Fluorescence In Situ Hybridization (FISH)
The FGFR2 gene, localized to chromosome 10q26, encodes a receptor tyrosine kinase involved in growth signaling. Oncogenic rearrangements involving this gene are well-described in approximately 6-17% cholangiocarcinoma and have also been reportedly less commonly in other cancers including colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer, breast carcinoma, and prostatic adenocarcinoma. Infigratinib and pemigatinib are efficacious in advanced or metastatic cholangiocarcinomas with FGFR2 rearrangements and are now FDA-approved for this indication.
Interpretive report provided.
This test will detect rearrangements involving FGFR2 but will not identify the translocation partner. This test may fail to detect intrachromosomal rearrangements or submicroscopic insertions in some cases.
3 – 10 days
A formalin-fixed, paraffin-embedded tissue block (containing sufficient neoplastic cells) is preferred. Unstained slides (3 slides cut at 4-microns) with associated H&E-stained slide are also acceptable. Decalcified tissue or tissues with other fixatives will be accepted and the assay attempted; however, these specimens may result in failed testing due to degraded nucleic acid. Both blocks and slides should be stored at room temperature.
By ordering this test the clinician acknowledges that informed consent has been obtained from the patient as required by applicable state or federal laws and the ordering clinician has authorization from the patient permitting MLabs to report the test results to the ordering clinician. Test includes pathologist interpretation of results billed as a separate additional charge. This test is not available without interpretation.